Stocks · Healthcare · Biotechnology
ImageneBio Inc IMA
$4.60 +0.44% Close, Oct 2, 2026 · NASDAQ · Market cap $51.9M
Weak trendExpensive vs sector
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 571.6% in a year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
- Over the past year the stock returned -45.9%, behind the S&P 500 by 61.0 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth, 3-year CAGRBottom 2%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 33%
- Accruals (lower is better)Bottom 11%
- Interest coverBottom 7%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 5%
- Free-cash-flow yieldBottom 2%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 10%
- 6-month returnBottom 35%
- 1-year return vs S&P 500Bottom 12%
- Distance from 52-week highBottom 30%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 29%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 45%
- Upside to consensus price targetBottom 1%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 32%
- Maximum drawdown, 3 yearsBottom 12%
- Beta vs S&P 500 (lower is better)Top 45%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -39.8% | — | Bottom 33% | |
| Revenue growth, 3-year CAGR | -62.9% | — | Bottom 2% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 3.5%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -614.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -174.70%
- Shareholder yield
- -174.70%
- Share count change, 1 year
- +571.6%
- Share count change, 3-year CAGR
- +70.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- -10.2%
- Average 2-day reaction, last 8
- -0.3%
- Positive 20 days after report
- 1 of 8
Analysts
- Consensus price target
- $1.33
- Target vs current price
- -71.1%
- Analysts with a rating
- 5
- Share rating Buy or Strong Buy
- 80%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +35.5% | +0.7% | -1.8% | -12.1% | — |
| May 7, 2026 | -35.7% | -2.8% | -5.1% | -6.4% | -7.2% |
| Mar 5, 2026 | +57.2% | -1.8% | -2.3% | -17.9% | -4.4% |
| Nov 12, 2025 | -98.0% | -0.7% | -11.4% | -25.3% | -14.5% |
| Jul 24, 2025 | +57.1% | -0.7% | -7.7% | -15.2% | -54.2% |
| May 8, 2025 | +14.3% | -0.9% | -0.9% | +19.3% | +26.9% |
| Mar 6, 2025 | +21.7% | +5.9% | +3.0% | -7.4% | -11.9% |
| Nov 7, 2024 | +22.2% | -1.7% | +1.2% | -2.3% | -15.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.63 | -$0.98 | +35.5% | — |
| May 7, 2026 | -$0.95 | -$0.70 | -35.7% | — |
| Mar 5, 2026 | -$0.62 | -$1.45 | +57.2% | — |
| Nov 12, 2025 | -$2.91 | -$1.47 | -98.0% | — |
| Jul 24, 2025 | -$0.06 | -$0.14 | +57.1% | -$500,000 |
| May 8, 2025 | -$0.18 | -$0.21 | +14.3% | $800,000 |
| Mar 6, 2025 | -$0.18 | -$0.23 | +21.7% | — |
| Nov 7, 2024 | -$0.21 | -$0.27 | +22.2% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -111.27% | — | — | Bottom 2% |
| Earnings yield | -113.26% | — | — | Bottom 5% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.4%
- 200-day average slope (20 days)
- -3.3%
- Distance from 50-day average
- -12.7%
- Distance from 200-day average
- -21.5%
- RSI (14)
- 32.1
- Relative volume
- 0.46×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 46.1%
- Volatility vs own 5-year history
- 13th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.02
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -47.7%
- Maximum drawdown, 3 years
- -91.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 26, 2021 | Apr 6, 2026 | -98.8% | 1261 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $51.9M
- EPS, diluted (TTM)
- -$5.21
- Revenue (TTM)
- $0
- 52-week range
- $3.94 – $9.10
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $31.0M | $15.6M | $9.2M | $3.5M | $800,000 |
| Gross profit | -$16.1M | -$48.7M | $8.1M | $2.0M | -$233,000 |
| Operating income | -$34.1M | -$70.9M | -$75.4M | -$37.0M | -$48.5M |
| Net income | -$34.1M | -$68.8M | -$68.2M | -$36.6M | -$45.3M |
| EPS (diluted) | -$11.38 | -$22.80 | -$19.60 | -$40.52 | -$9.64 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $800,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$10.2M | -$9.1M | -$6.1M | -$2.8M | -$24.8M | -$6.9M | -$10.6M | -$10.2M |
| EPS (diluted) | -$4.41 | -$5.58 | -$6.47 | -$4.46 | -$3.01 | -$0.62 | -$0.95 | -$0.63 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$60.3M | -$74.1M | -$79.7M | -$46.0M | -$47.8M |
| Capital expenditure | -$1.8M | -$1.4M | -$414,000 | $0 | $0 |
| Free cash flow | -$62.0M | -$75.5M | -$80.2M | -$46.0M | -$47.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $131.3M | $0 | $36.9M | $0 | $65.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $136.2M
- Total assets
- $152.0M
- Total liabilities
- $10.0M
- Total debt
- $1.9M
- Net debt
- -$92.8M
- Shareholders’ equity
- $142.1M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 34,601
- Days to cover
- 2.30
- Change vs previous report
- -12.2%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 28, 2025
- 1-for-12